15.36
-0.45%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Ascentage Pharma Group International
Its shares trade under the ticker AAPG. It has been listed since 24 January 2025. In the fiscal year to 31 December 2025, it reported revenue of $83.1m and a net loss of $179.8m. At that date it held total assets of $589.9m and shareholders' equity of $197.1m.
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 24 Jan 2025
- Employees
- 767
- Website
- ascentage.cn ↗
- Head office
- 68 XINQING ROAD, SUZHOU , JIANGSU
- Incorporated in
- E9
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Emerging growth company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HQP1351 targets BCR-ABL1 mutants including T315I mutation in Mainland China.
- APG-2575 treats hematologic malignancies and solid tumors in China.
- APG-1387 addresses advanced solid tumors and chronic HBV infection in China.
Weaknesses
- Limited clinical-stage biotechnology focus on Mainland China only.
- No international market expansion mentioned for APG-115 and APG-1252.
- No data on employee productivity or operational efficiency in the facts.
Opportunities
- HQP1351 development for BCR-ABL1 mutants in Mainland China.
- APG-2575 expansion into hematologic malignancies in China.
- APG-1387 potential for chronic HBV infection treatment in China.
Threats
- No international regulatory approvals mentioned for HQP1351.
- No mention of competition in Mainland China for APG-115.
- No data on clinical trial success rates for APG-1252.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.